![Jan Mikkelsen](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jan Mikkelsen
Patrimonio netto: 93 M $ in data 31/12/2025
Profilo
Jan M. Mikkelsen è amministratore delegato e direttore di Ascendis Pharma Endocrinology Division A/S, presidente, amministratore delegato e direttore esecutivo di Ascendis Pharma A/S, amministratore delegato di Ascendis Pharma Bone Diseases A/S e amministratore delegato di Ascendis Pharma Growth Disorders AS. Fa parte del consiglio di amministrazione di Ascendis Pharma Endocrinology Division A/S, Ascendis Pharma A/S e Visen Pharmaceuticals (Shanghai) Co. Ltd. Mikkelsen è stato precedentemente impiegato come presidente e amministratore delegato di LifeCycle Pharma A/S, presidente della divisione farmaceutica di Maxygen, Inc., co-amministratore delegato di Profound Pharma AS e vicepresidente di Novo Nordisk A/S. Si è laureato presso l'Università della Danimarca meridionale.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
ASCENDIS PHARMA A/S 0,72% | 31/12/2024 | 438.250 ( 0,72% ) | 93 M $ | 31/12/2025 |
Posizioni attive di Jan Mikkelsen
| Società | Posizione | Inizio |
|---|---|---|
| ASCENDIS PHARMA A/S | Fondatore | 21/09/2006 |
Ascendis Pharma Endocrinology Division A/S
 Ascendis Pharma Endocrinology Division A/S Manufactures endocrine pharmaceutical products | Amministratore Delegato | 29/06/2012 |
VISEN Pharmaceuticals (Shanghai) Co., Ltd.
 VISEN Pharmaceuticals (Shanghai) Co., Ltd. Manufactures pharmaceuticals | Direttore/Membro del Consiglio | - |
Ascendis Pharma Bone Diseases A/S | Amministratore Delegato | - |
Ascendis Pharma Growth Disorders AS | Amministratore Delegato | - |
Frazier Management LLC
 Frazier Management LLC Investment ManagersFinance Frazier Healthcare Partners invests in companies located in the United States with an EBITDA of USD10 million - USD75 million. The firm focuses on sectors such as science, pharmaceuticals and healthcare services. It participates in mezzanine financing for late private/public opportunities, buyouts, recapitalizations, corporate carve-outs, seed, early and later stage with an investment size of USD50 million - USD400 million. | Consulente / Consigliere | 01/01/2022 |
Hummingbird Bioscience Holdings Pte Ltd.
 Hummingbird Bioscience Holdings Pte Ltd. Functions as an investment holding company | Presidente | 01/01/2021 |
Precedenti posizioni note di Jan Mikkelsen
| Società | Posizione | Fine |
|---|---|---|
| VISEN PHARMACEUTICALS | Direttore/Membro del Consiglio | 27/06/2025 |
| VELOXIS PHARMACEUTICALS A/S | Amministratore Delegato | 01/01/2006 |
| ░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░ ░░ | ░░░░░░░░░░░░░░ ░░░░░░░░ | - |
| ░░░░ ░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Formazione di Jan Mikkelsen
Esperienze
Posizioni ricoperte
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 13 |
|---|---|
Frazier Management LLC
Frazier Management LLC Investment ManagersFinance Frazier Healthcare Partners invests in companies located in the United States with an EBITDA of USD10 million - USD75 million. The firm focuses on sectors such as science, pharmaceuticals and healthcare services. It participates in mezzanine financing for late private/public opportunities, buyouts, recapitalizations, corporate carve-outs, seed, early and later stage with an investment size of USD50 million - USD400 million. | Finance |
Maxygen, Inc.
 Maxygen, Inc. Miscellaneous Commercial ServicesCommercial Services Develops directed molecular evolution technology | Commercial Services |
Novo Nordisk A/S
 Novo Nordisk A/S Pharmaceuticals: MajorHealth Technology Manufactures and markets pharmaceutical products for diabetes care | Health Technology |
Veloxis Pharmaceuticals A/S
 Veloxis Pharmaceuticals A/S Pharmaceuticals: MajorHealth Technology Develops and commercializes medicines for the prevention of organ rejection in kidney transplant patients | Health Technology |
Profound Pharma AS
 Profound Pharma AS Pharmaceuticals: MajorHealth Technology Provides pharmaceutical products | Health Technology |
University of Southern Denmark
 University of Southern Denmark Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ascendis Pharma A/S
 Ascendis Pharma A/S Pharmaceuticals: MajorHealth Technology Develops drug candidates | Health Technology |
Ascendis Pharma Endocrinology Division A/S
Ascendis Pharma Endocrinology Division A/S Manufactures endocrine pharmaceutical products | |
VISEN Pharmaceuticals (Shanghai) Co., Ltd.
VISEN Pharmaceuticals (Shanghai) Co., Ltd. Manufactures pharmaceuticals | |
Ascendis Pharma Bone Diseases A/S | |
Hummingbird Bioscience Holdings Pte Ltd.
Hummingbird Bioscience Holdings Pte Ltd. Functions as an investment holding company | |
Ascendis Pharma Growth Disorders AS | |
VISEN Pharmaceuticals
 VISEN Pharmaceuticals Develops, manufactures and commercializes paradigm-shifting endocrine therapies |
